Likewise, the CXCR4 antagonist TG-0054 (Burixafor, ChemoCentryx) and the aptamer Nox-A12 (Spiegelmer, Noxxon), an anti-CXCL12/SDF-1, are currently being tested in clinical trials in combination with chemotherapy for multiple myeloma and for chronic lymphatic leukaemia [126]. This evidence concerns the gene CXCL12 and B-cell chronic lymphocytic leukemia.